147 related articles for article (PubMed ID: 32649622)
1. Chronic kidney disease as a cardiovascular risk factor.
Carmena R; Ascaso JF; Redon J
J Hypertens; 2020 Nov; 38(11):2110-2121. PubMed ID: 32649622
[TBL] [Abstract][Full Text] [Related]
2. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
3. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting.
Völler H; Gitt A; Jannowitz C; Karoff M; Karmann B; Pittrow D; Reibis R; Hildemann S
Eur J Prev Cardiol; 2014 Sep; 21(9):1125-33. PubMed ID: 23508927
[TBL] [Abstract][Full Text] [Related]
5. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
[TBL] [Abstract][Full Text] [Related]
6. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
7. Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital.
Sangsawang T; Sriwijitkamol A
Vasc Health Risk Manag; 2015; 11():563-7. PubMed ID: 26604773
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy.
Yan X; Li Y; Dong Y; Wu Y; Li J; Bian R; Hu D
Lipids Health Dis; 2019 Jan; 18(1):32. PubMed ID: 30696435
[TBL] [Abstract][Full Text] [Related]
9. [Ezetimibe as a treatment for dyslipidaemia in CKD].
Żebrowski P; Kaszyńska M
Wiad Lek; 2019; 72(11 cz 2):2210-2213. PubMed ID: 31860838
[TBL] [Abstract][Full Text] [Related]
10. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
11. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
Pennell P; Leclercq B; Delahunty MI; Walters BA
Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
[TBL] [Abstract][Full Text] [Related]
12. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
13. The MAURO study: baseline characteristics and compliance with guidelines targets.
Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
[TBL] [Abstract][Full Text] [Related]
14. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
Khurana M; Silverstein DM
Pediatr Nephrol; 2015 Dec; 30(12):2073-84. PubMed ID: 25801207
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy in dyslipidemia: where are we now?
Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
[TBL] [Abstract][Full Text] [Related]
16. Impact of Chronic Kidney Disease on Risk for Vascular Events.
Fan J; Salameh H
Curr Vasc Pharmacol; 2016; 14(5):409-414. PubMed ID: 27456102
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes.
Cavallari I; Delli Veneri A; Maddaloni E; Melfi R; Patti G; Napoli N; Pozzilli P; Di Sciascio G
Curr Diab Rep; 2018 Oct; 18(12):138. PubMed ID: 30370486
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
